BioSpace News Archive

QIAGEN N.V. (NYSE: QGEN; Frankfurt Prime Standard: QIA) (“QIAGEN” or the “Company”) announces it has begun a review of potential strategic alternatives after receiving several conditional, non-binding indications of interest for the acquisition of all issued and outstanding shares of the Company.

Novartis announced today that the US Food and Drug Administration (FDA) approved Adakveo® (crizanlizumab-tmca), previously known as SEG101, to reduce the frequency of vaso-occlusive crises (VOCs), or pain crises, in adult and pediatric patients aged 16 years and older with sickle cell disease

Bristol-Myers Squibb Company (NYSE:BMY) announced today that the U.S. Federal Trade Commission (FTC) has accepted the proposed consent order in connection with the pending merger of Bristol-Myers Squibb and Celgene Corporation (NASDAQ:CELG), thereby permitting the parties to close the transaction.

HEXO Corp (TSX: HEXO; NYSE: HEXO) (“HEXO” or the “Company”) is providing additional information about licensing at its facility in Niagara, Ontario.

Predictive Oncology Inc., (NASDAQ: POAI) (“Predictive Oncology” or “the Company”) an artificial intelligence (AI) and data-driven functional precision medicine company with the mission of improving the standard of care for cancer patients through innovative data-driven products and services announced financial results for the quarter ended September 30, 2019 and provided a business update.

“Based on our traceback investigation of recent cases of Scombrotoxin fish poisoning, the FDA is warning all sectors of the supply chain to discard certain tuna supplied by Truong Phu Xanh Co., LTD of Vietnam and advising consumers not eat any of this product.

Apellis Pharmaceuticals Inc. (Nasdaq: APLS), a clinical-stage biopharmaceutical company focused on the development of novel therapeutic compounds to treat disease through the inhibition of the complement system, today announced that the Company approved the grant of an equity award to a new employee with a grant date of November 11, 2019 as an equity inducement award

The U.S. Food and Drug Administration today approved the first contact lens indicated to slow the progression of myopia (nearsightedness) in children between the ages of 8 and 12 years old at the initiation of treatment

Maxar Technologies Inc. (NYSE: MAXR) (TSX:MAXR), a trusted partner and innovator in Earth Intelligence and Space Infrastructure, today announced the pricing of $1.0 billion in aggregate principal amount of 9.75% Senior Secured Notes due 2023 issued by SSL Robotics LLC, its wholly-owned subsidiary.

LeMaitre Vascular, Inc. (Nasdaq:LMAT) announced today that it will be presenting at two conferences in November.